 Primary prophylaxis Pneumocystis carinii pneumonia HIV-infected people counts cost-effectiveness analysis decision-analytic model effectiveness costs dapsone trimethoprim-sulfamethoxazole aerosolized pentamidine initial prophylaxis Pneumocystis carinii pneumonia human immunodeficiency virus-infected people prior symptoms AIDS strategy life expectancy prophylaxis annual per-person costs dapsone trimethoprim-sulfamethoxazole aerosolized pentamidine cost differences strategy dapsone cost effective incremental cost-effectiveness ratio life year prophylaxis Aerosolized pentamidine cost effective incremental cost effectiveness ratios dependent estimates quality life efficacy toxicity compliance available data initial prophylaxis dapsone trimethoprim-sulfamethoxazole cost effective people prophylaxis trimethoprim-sulfamethoxazole dapsone crossover pentamidine oral therapy year